Atrasentan is an experimental drug that is being studied for the treatment of various types of cancer including non-small cell lung cancer.It is an endothelin receptor antagonist selective for subtype A (ETA). While other drugs of this type (sitaxentan ambrisentan) exploit the vasoconstrictive properties of endothelin and are mainly used for the treatment of pulmonary arterial hypertension atrasentan blocks endothelin induced cell proliferation.
This page contains content from the copyrighted Wikipedia article "Atrasentan"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
